Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment

Durvalumab, a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules, is increasingly used in advanced neoplasias. Durvalumab use is associated with increased immune-related adverse events. We re...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Endocrinol Diabetes Metab Case Rep
Hlavní autoři: León Mengíbar, Jose, Capel, Ismael, Bonfill, Teresa, Mazarico, Isabel, Casamitjana Espuña, Laia, Caixàs, Assumpta, Rigla, Mercedes
Médium: Artigo
Jazyk:Inglês
Vydáno: Bioscientifica Ltd 2019
Témata:
Unusual Effects of Medical Treatment
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8115434/
https://ncbi.nlm.nih.gov/pubmed/31310083
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EDM-19-0045
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky